{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:37:50Z","timestamp":1791729470128,"version":"4.3.4"},"reference-count":20,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2344,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1111\/j.1365-2710.2008.00994.x","type":"journal-article","created":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T12:02:08Z","timestamp":1227614528000},"page":"207-213","source":"Crossref","is-referenced-by-count":36,"title":["Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach"],"prefix":"10.1155","volume":"34","author":[{"given":"M.","family":"Campara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Shord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Haaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","reference":[{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB1","first-page":"117","article-title":"Managing malignancy-associated hyperuricemia with rasburicase","volume":"3","author":"Cheson","year":"2005","journal-title":"The Journal of Support Oncology"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB2","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"Randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1345\/aph.1G272","article-title":"Hemolysis and methemoglobinemia secondary to rasburicase administration","volume":"39","author":"Browning","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB4","volume-title":"Product information: Elitek(R), rasburicase","author":"Anonymous","year":"2007"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.11612","article-title":"Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study","volume":"98","author":"Bosly","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB6","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","article-title":"Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin\u2019s lymphoma: results of the GRAAL1 (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Trial on Rasburicase Activity in Adult Lymphoma) study","volume":"21","author":"Coiffier","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB8","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","article-title":"Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial","volume":"15","author":"Pui","year":"2001","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB9","volume-title":"Red book","author":"Anonymous","year":"2006"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB10","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-0609.2005.00550.x","article-title":"Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase","volume":"75","author":"Hummel","year":"2005","journal-title":"European Journal of Haematology"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1592\/phco.26.2.242","article-title":"Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy","volume":"26","author":"Hutcherson","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB13","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1345\/aph.1D111","article-title":"Treatment of impending tumor lysis with single-dose rasburicase","volume":"37","author":"Lee","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.leukres.2004.09.004","article-title":"A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy","volume":"29","author":"Liu","year":"2005","journal-title":"Leukemia Research"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1705379","article-title":"Reduceddose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia","volume":"37","author":"Trifilio","year":"2006","journal-title":"Bone Marrow Transplantation"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1542\/peds.82.6.863","article-title":"Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma","volume":"82","author":"Stapleton","year":"1988","journal-title":"Pediatrics"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.1996.14.4.1252","article-title":"Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study","volume":"14","author":"Bowman","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB18","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/bjc.1998.379","article-title":"Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin\u2019s lymphoma (B-NHL) - results of the UKCCSG 9003 protocol","volume":"77","author":"Atra","year":"1998","journal-title":"British Journal of Cancer"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.26.6.806","article-title":"Single-dose rasburicase 6\u2003mg in the management of tumor lysis syndrome in adults","volume":"26","author":"McDonnell","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2008.00994.x-BIB20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1345\/aph.1E002","article-title":"Use of single-dose rasburicase in an obese female","volume":"38","author":"Arnold","year":"2004","journal-title":"Annals of Pharmacotherapy"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2008.00994.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2008.00994.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T13:32:47Z","timestamp":1684675967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2008.00994.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00994.x","relation":{},"ISSN":["0269-4727","1365-2710"],"issn-type":[{"value":"0269-4727","type":"print"},{"value":"1365-2710","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}